Go to deals
Healthcare

Igyxos S.A. has completed a Series A fundraising

Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.

Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.

Oaklins' team in France advised Igyxos in a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Jean-Paul  Ortelli

Jean-Paul Ortelli

Senior Advisor

Paris, France
Oaklins France
 Leïla  Djebli

Leïla Djebli

Associate Director

Paris, France
Oaklins France

Related deals

BlijWerkt has been acquired by Mentha Capital
Business Support Services | Healthcare | Private Equity

BlijWerkt has been acquired by Mentha Capital

Gilde Healthcare Partners has sold BlijWerkt Groep B.V. to Mentha Capital.

Learn more
Medical Mutual of Ohio has acquired Bravo Wellness, LLC
Healthcare

Medical Mutual of Ohio has acquired Bravo Wellness, LLC

Medical Mutual of Ohio on the acquisition of Bravo Wellness, LLC.

Learn more
Lead Healthcare has successfully raised financing provided by Rabobank
Healthcare

Lead Healthcare has successfully raised financing provided by Rabobank

Lead Healthcare has successfully raised financing provided by Rabobank.

Learn more